Tarsus completes Alkeus acquisition, adding late-stage Stargardt drug ALK-001
AI Summary- Tarsus completed its acquisition of Alkeus and added worldwide ALK-001 rights.
- NORTHSTAR Phase 3 topline data are anticipated in 2029.
- Stargardt disease affects as many as 86,000 people in the United States.